asa glp 1 GLP-1 and Anesthesia: Considerations and Cautions for CRNAs Less than half of Brits

As GLP-1 receptor agonists continue to be widely adopted for obesity and metabolic disease, it is essential to consider their broader implications for bone health and orthopedic surgery

Gala K, Tome J, Krall M, et al

They should be aware of the specific criteria for GLP-1 approval for weight loss

Consequently, once-daily subcutaneous administration of liraglutide 3.0 mg was developed for the treatment of obesity [21] and once-weekly subcutaneous administration of semaglutide 2.4 mg is currently being investigated in phase III trials for this indication [22]

With several FDA-approved options available, more people now have access to medications that can deliver meaningful results

The Core Difference: How They Fuel Weight Loss Both Wegovy and Zepbound belong to the class of medications known as GLP-1 (Glucagon-Like Peptide-1) agonists, which mimic natural gut hormones to regulate appetite, slow digestion, and improve metabolic health